Becton Dickinson and (BDX)
NYSE: BDX
· Real-Time Price · USD
195.15
-0.79 (-0.40%)
At close: Aug 18, 2025, 3:59 PM
195.00
-0.08%
After-hours: Aug 18, 2025, 07:44 PM EDT
Becton Dickinson and Revenue Breakdown
Period Ending | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | Sep 30, 2015 | Sep 30, 2014 | Sep 30, 2013 | Sep 30, 2012 | Sep 30, 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Interventional Revenue | 4.98B | 5.13B | 4.46B | 4.24B | 3.76B | 3.93B | 3.04B | 3.99B | 3.83B | 6.46B | 4.57B | 4.31B | 4.09B | 4.01B |
Interventional Revenue Growth | -2.98% | +14.99% | +5.31% | +12.68% | -4.18% | +29.27% | -23.85% | +4.15% | -40.73% | +41.26% | +6.20% | +5.26% | +2.08% | n/a |
Life Sciences Revenue | 5.19B | 9.5B | 5.56B | 6.53B | 4.67B | 4.3B | 4.33B | 8.11B | 8.65B | 3.82B | n/a | n/a | n/a | n/a |
Life Sciences Revenue Growth | -45.37% | +70.78% | -14.79% | +39.68% | +8.72% | -0.69% | -46.58% | -6.34% | +126.43% | n/a | n/a | n/a | n/a | n/a |
Medical Revenue | 10.07B | 4.74B | 8.84B | 9.48B | 8.68B | 9.06B | 8.62B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Medical Revenue Growth | +112.71% | -46.43% | -6.73% | +9.21% | -4.24% | +5.20% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
Period Ending | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | Sep 30, 2015 | Sep 30, 2014 | Sep 30, 2013 | Sep 30, 2012 | Sep 30, 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Asia Revenue | 2.91B | 2.91B | 3.05B | 3.27B | 2.57B | 2.73B | 2.46B | 1.74B | 1.69B | 1.54B | 1.12B | 1.01B | 883.29M | 684.32M |
Asia Revenue Growth | -0.24% | -4.40% | -6.88% | +27.41% | -5.80% | +10.81% | +41.06% | +3.07% | +9.51% | +37.82% | +11.43% | +13.89% | +29.08% | n/a |
Europe Revenue | 4.4B | 4.24B | 4.04B | 4.75B | 3.48B | 3.36B | 3.3B | 2.59B | 3.05B | 2.43B | 2.73B | 2.51B | 2.38B | 2.39B |
Europe Revenue Growth | +3.72% | +4.97% | -14.90% | +36.52% | +3.60% | +1.85% | +27.43% | -15.12% | +25.27% | -10.94% | +8.80% | +5.60% | -0.34% | n/a |
Others Country Revenue | 1.21B | 1.1B | 1.06B | 1.25B | 1.35B | 1.48B | 1.46B | 1.26B | 849M | 1.23B | 1.18B | 1.18B | 1.16B | 1.01B |
Others Country Revenue Growth | +9.53% | +4.16% | -15.70% | -7.24% | -8.33% | +1.30% | +15.91% | +48.06% | -31.20% | +5.02% | -0.68% | +2.10% | +14.21% | n/a |
United States Revenue | 11.66B | 11.11B | 10.72B | 10.97B | 9.72B | 9.73B | 8.77B | 6.5B | 6.89B | 5.07B | 3.42B | 3.35B | 3.29B | 3.29B |
United States Revenue Growth | +4.95% | +3.65% | -2.25% | +12.90% | -0.14% | +10.97% | +34.81% | -5.64% | +35.98% | +48.35% | +1.91% | +1.99% | +0.03% | n/a |
Operating Expense Breakdown
Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 1.32B | 1.27B | 1.32B | 1.26B | 1.2B | 1.19B | 1.21B | 1.14B | 1.19B | 1.21B | 1.19B | 1.18B | 1.15B | 1.19B | 1.19B | 1.33B | 1.2B | 1.15B | 1.15B | 1.2B | 980M | 1.02B | 1.12B | 1.09B | 1.08B | 1.09B | 1.07B | 1.1B | 1.09B | 1.06B | 773M | 774M | 719M | 724M | 709M | 796M | 728M | 732M | 748M | 743M | 751M | 511M |
Selling, General, and Administrative Revenue Growth | +3.69% | -3.41% | +4.94% | +5.02% | +0.25% | -1.65% | +6.59% | -4.37% | -1.24% | +1.52% | +0.42% | +2.87% | -3.61% | +0.59% | -11.04% | +11.00% | +4.53% | -0.09% | -4.17% | +22.35% | -4.39% | -8.56% | +2.47% | +1.67% | -1.19% | +1.49% | -2.72% | +1.57% | +2.84% | +36.61% | -0.13% | +7.65% | -0.69% | +2.12% | -10.93% | +9.34% | -0.55% | -2.14% | +0.67% | -1.07% | +46.97% | n/a |
Research and Development Revenue | 297M | 302M | 343M | 302M | 299M | 299M | 290M | 281M | 306M | 337M | 313M | 300M | 315M | 327M | 314M | 387M | 330M | 317M | 291M | 299M | 262M | 264M | 270M | 270M | 282M | 252M | 258M | 278M | 277M | 259M | 191M | 220M | 186M | 187M | 182M | 253M | 207M | 182M | 187M | 195M | 178M | 129M |
Research and Development Revenue Growth | -1.66% | -11.95% | +13.58% | +1.00% | 0.00% | +3.10% | +3.20% | -8.17% | -9.20% | +7.67% | +4.33% | -4.76% | -3.67% | +4.14% | -18.86% | +17.27% | +4.10% | +8.93% | -2.68% | +14.12% | -0.76% | -2.22% | 0.00% | -4.26% | +11.90% | -2.33% | -7.19% | +0.36% | +6.95% | +35.60% | -13.18% | +18.28% | -0.53% | +2.75% | -28.06% | +22.22% | +13.74% | -2.67% | -4.10% | +9.55% | +37.98% | n/a |